Epilive ER 500 Tablet contains Levetiracetam 500mg, an antiepileptic medication indicated for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure activity. Epilive ER 500 is formulated as an extended-release tablet to provide sustained plasma concentrations, allowing once-daily dosing and improved patient compliance. It is generally well tolerated, with common adverse effects including somnolence, dizziness, fatigue, and headache. Dose adjustments may be necessary in patients with renal impairment due to renal excretion of the drug. Epilive ER 500 should be used under medical supervision, with gradual titration to minimize side effects and optimize therapeutic outcomes. It is important to adhere to prescribed dosing schedules and not to discontinue therapy abruptly to avoid seizure exacerbation. Epilive ER 500 may be used as monotherapy or adjunctive therapy in adults and pediatric patients aged four years and above. Regular monitoring of clinical response and adverse effects is recommended during treatment. Patients should inform their healthcare provider of any concomitant medications to avoid potential drug interactions.